Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.

Abstract: The present disclosure relates to methods, devices and systems used for the treatment of medical disorders via stimulation of the superficial elements of the trigeminal nerve. More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein.

Abstract: The present disclosure relates to methods, devices and systems used for the treatment of medical disorders via stimulation of the superficial elements of the trigeminal nerve. More specifically, cutaneous methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, infraorbital, nasal and mentalis nerves also referred to collectively as the superficial trigeminal nerve) are disclosed herein.

Abstract: A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically.

Abstract: Described herein is an implantable device including: a housing including a connection opening defined therein, wherein the connection opening includes posts and slots and is configured to receive at least one connection associated with a neuromodulation device; a connection holding cap having posts, wherein the posts are configured to oppose the posts of the connection opening and wherein the connection holding cap is configured to receive the at least one connection associated with the neuromodulation device and configured to be operably connected to the connection opening by interconnecting the opposing posts after receiving the at least one connection associated with the neuromodulation device; a neuromodulation device holder operably connected to the device housing and configured to receive the neuromodulation device and secure the neuromodulation device within the device housing; and a cover operably connected to the device housing and configured to seal the device housing.

Abstract: Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.

Abstract: Methods and systems for treating anxiety disorders and disorders with psychotic features include implanting at least one electrode in the patient so as to contact a predetermined region of the brain, coupling the at least one electrode to a signal generating source and transmitting an electrical signal from the source to the predetermined region of the brain through the at least one electrode. In one aspect, the predetermined region of the brain is the amygdala, and more specifically, the basolateral nucleus.